Acceleron Announces Closing of Public Offering of Common Stock & Exercise of Underwriters’ Option to Purchase Additional Sh...
07 Julio 2020 - 3:04PM
Business Wire
Acceleron Pharma Inc. (Nasdaq: XLRN), a leading
biopharmaceutical company in the discovery, development, and
commercialization of TGF-beta superfamily therapeutics to treat
serious and rare diseases, today announced that it has issued an
aggregate of 5,594,593 shares of common stock at a price of $92.50
per share at the closing of the Company’s previously-announced
public offering. The aggregate net proceeds to the Company of the
public offering, including pursuant to the full exercise of the
underwriters’ option to purchase additional shares and after
deducting underwriting discounts and commissions and estimated
offering expenses, were approximately $492.5 million.
J.P. Morgan, SVB Leerink and Cowen acted as joint book-runners
for the offering. Barclays, Credit Suisse, and Piper Sandler &
Co. also acted as joint book-running managers. H.C. Wainwright
& Co. acted as lead manager.
The shares were offered by Acceleron pursuant to an effective
shelf registration statement on Form S-3 that was previously filed
with the Securities and Exchange Commission (the "SEC"). A
preliminary prospectus supplement relating to and describing the
terms of the offering was filed with the SEC on June 30, 2020. The
final prospectus supplement relating to the offering was filed with
the SEC on July 2, 2020. Copies of the final prospectus supplement
and the accompanying prospectus can be obtained at the SEC's
website http://www.sec.gov or from J.P. Morgan Securities LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, by telephone at (866) 803-9204; or by email at
Prospectus-eq_fi@jpmchase.com; SVB Leerink LLC, by mail at One
Federal Street, 37th Floor, Boston, MA 02110, Attention: Syndicate
Department, by telephone at (800) 808-7525, ext. 6218, or by email
at syndicate@svbleerink.com; and Cowen and Company, LLC c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY,11717, Attn: Prospectus Department, by email at
PostSaleManualRequests@broadridge.com or by telephone at (833)
297-2926.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy the securities in the offering, nor
shall there be any sale of these securities in any jurisdiction in
which an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of such
jurisdiction.
About Acceleron
Acceleron is a biopharmaceutical company dedicated to the
discovery, development, and commercialization of therapeutics to
treat serious and rare diseases. Acceleron’s leadership in the
understanding of TGF-beta superfamily biology and protein
engineering generates innovative compounds that engage the body's
ability to regulate cellular growth and repair.
Acceleron focuses its commercialization, research, and
development efforts in hematologic and pulmonary diseases. In
hematology, Acceleron and its global collaboration partner, Bristol
Myers Squibb, are co-promoting REBLOZYL® (luspatercept-aamt), the
first and only approved erythroid maturation agent, in the United
States for the treatment of anemia in certain blood disorders. The
Companies are also developing luspatercept for the treatment of
anemia in patient populations of MDS, beta-thalassemia, and
myelofibrosis. In pulmonary, Acceleron is developing sotatercept
for the treatment of pulmonary arterial hypertension, having
recently reported positive topline results of the Phase 2 PULSAR
trial.
Cautionary Note on Forward-Looking Statements
Certain statements contained in this press release are
forward-looking statements that involve a number of risks and
uncertainties that could cause actual results to differ materially
from those in the forward-looking statements, including statements
about Acceleron’s strategy, future plans and prospects. The words
"anticipate," "believe," "could," "estimate," "expect," "goal,"
"intend," "may," "plan," "potential," "project," "should,"
"target," "will," "would," and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Actual
results could differ materially from those included in the
forward-looking statements due to various factors, risks and
uncertainties, including, but not limited to, risks and
uncertainties associated with the consummation of the proposed
offering, changes in general economic or regulatory conditions, and
the clinical development and commercialization of Acceleron’s
compounds. These and other risks and uncertainties are identified
under the heading “Risk Factors” included in Acceleron’s most
recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q,
and other filings that Acceleron has made and may make with the SEC
in the future. We caution investors not to place considerable
reliance on the forward-looking statements contained in this press
release. The forward-looking statements in this press release speak
only as of the date of this document, and we undertake no
obligation to update or revise any of the statements. Our business
is subject to substantial risks and uncertainties, including those
referenced above. Investors, potential investors, and others should
give careful consideration to these risks and uncertainties. The
forward-looking statements contained in this press release are
based on management's current views, plans, estimates, assumptions,
and projections with respect to future events, and Acceleron does
not undertake and specifically disclaims any obligation to update
any forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200707005881/en/
Acceleron Pharma Inc. Investors: Todd James, (617) 649-9393
Senior Vice President, Corporate Affairs and Investor Relations
Media: Matt Fearer, (617) 301-9557 Director, Corporate
Communications
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024